Anaplastic thyroid carcinoma: Biology, pathogenesis, prognostic factors, and treatment approaches

Chandrakanth Are, Ashok R. Shaha

Research output: Contribution to journalReview article

276 Citations (Scopus)

Abstract

Background: Anaplastic thyroid carcinoma (ATC) is one of the most aggressive solid tumors known to affect humans and carries a dismal prognosis. Our primary aim was to review its epidemiology, biology, risk factors, and prognostic indicators. We also reviewed the individual and combined roles of surgery, radiotherapy, chemotherapy, and newer therapeutic options in the management of ATC. Methods: An extensive literature review was conducted to include all published reports on ATC. The changing trends in the management of anaplastic thyroid cancer were analyzed to summarize the current practice of management of ATC. Results: Although ATC is rare, there has been a decline in its incidence worldwide. ATC accounts for more than half of the 1200 deaths per year attributed to thyroid cancer. Long-term survivors are rare, with > 75% and 50% of patients harboring cervical nodal disease and metastatic disease, respectively, at presentation. ATC can arise de novo or from preexisting well-differentiated thyroid cancer. Surgical management has shifted from tracheostomy only for palliation to curative resection when possible. Tracheostomy is performed for impending obstruction rather than for prophylaxis. Radiotherapy has evolved from postoperative administration only to preoperative treatment, combining preoperative and postoperative treatment and using higher doses, along with hyperfractionating and accelerating dose schedules. Chemotherapy has changed from monotherapy to combination therapy, and newer drugs such as paclitaxel show promise. Similarly, novel angiogenesis-inhibiting agents are currently being used, with early reports of some benefit. Conclusions: Despite multimodality approaches, ATC still carries a dismal prognosis. This should provoke innovative strategies beyond conventional methods to tackle this uniformly lethal disease.

Original languageEnglish (US)
Pages (from-to)453-464
Number of pages12
JournalAnnals of Surgical Oncology
Volume13
Issue number4
DOIs
StatePublished - Apr 1 2006

Fingerprint

Therapeutics
Tracheostomy
Thyroid Neoplasms
Radiotherapy
Anaplastic Thyroid Carcinoma
Drug Therapy
Practice Management
Paclitaxel
Combination Drug Therapy
Survivors
Appointments and Schedules
Epidemiology
Incidence
Neoplasms

Keywords

  • Anaplastic thyroid carcinoma
  • Biology
  • Pathogenesis
  • Prognostic factors
  • Treatment approaches

ASJC Scopus subject areas

  • Surgery
  • Oncology

Cite this

Anaplastic thyroid carcinoma : Biology, pathogenesis, prognostic factors, and treatment approaches. / Are, Chandrakanth; Shaha, Ashok R.

In: Annals of Surgical Oncology, Vol. 13, No. 4, 01.04.2006, p. 453-464.

Research output: Contribution to journalReview article

@article{6298b0ea8a9e44b6a42924ef4156297e,
title = "Anaplastic thyroid carcinoma: Biology, pathogenesis, prognostic factors, and treatment approaches",
abstract = "Background: Anaplastic thyroid carcinoma (ATC) is one of the most aggressive solid tumors known to affect humans and carries a dismal prognosis. Our primary aim was to review its epidemiology, biology, risk factors, and prognostic indicators. We also reviewed the individual and combined roles of surgery, radiotherapy, chemotherapy, and newer therapeutic options in the management of ATC. Methods: An extensive literature review was conducted to include all published reports on ATC. The changing trends in the management of anaplastic thyroid cancer were analyzed to summarize the current practice of management of ATC. Results: Although ATC is rare, there has been a decline in its incidence worldwide. ATC accounts for more than half of the 1200 deaths per year attributed to thyroid cancer. Long-term survivors are rare, with > 75{\%} and 50{\%} of patients harboring cervical nodal disease and metastatic disease, respectively, at presentation. ATC can arise de novo or from preexisting well-differentiated thyroid cancer. Surgical management has shifted from tracheostomy only for palliation to curative resection when possible. Tracheostomy is performed for impending obstruction rather than for prophylaxis. Radiotherapy has evolved from postoperative administration only to preoperative treatment, combining preoperative and postoperative treatment and using higher doses, along with hyperfractionating and accelerating dose schedules. Chemotherapy has changed from monotherapy to combination therapy, and newer drugs such as paclitaxel show promise. Similarly, novel angiogenesis-inhibiting agents are currently being used, with early reports of some benefit. Conclusions: Despite multimodality approaches, ATC still carries a dismal prognosis. This should provoke innovative strategies beyond conventional methods to tackle this uniformly lethal disease.",
keywords = "Anaplastic thyroid carcinoma, Biology, Pathogenesis, Prognostic factors, Treatment approaches",
author = "Chandrakanth Are and Shaha, {Ashok R.}",
year = "2006",
month = "4",
day = "1",
doi = "10.1245/ASO.2006.05.042",
language = "English (US)",
volume = "13",
pages = "453--464",
journal = "Annals of Surgical Oncology",
issn = "1068-9265",
publisher = "Springer New York",
number = "4",

}

TY - JOUR

T1 - Anaplastic thyroid carcinoma

T2 - Biology, pathogenesis, prognostic factors, and treatment approaches

AU - Are, Chandrakanth

AU - Shaha, Ashok R.

PY - 2006/4/1

Y1 - 2006/4/1

N2 - Background: Anaplastic thyroid carcinoma (ATC) is one of the most aggressive solid tumors known to affect humans and carries a dismal prognosis. Our primary aim was to review its epidemiology, biology, risk factors, and prognostic indicators. We also reviewed the individual and combined roles of surgery, radiotherapy, chemotherapy, and newer therapeutic options in the management of ATC. Methods: An extensive literature review was conducted to include all published reports on ATC. The changing trends in the management of anaplastic thyroid cancer were analyzed to summarize the current practice of management of ATC. Results: Although ATC is rare, there has been a decline in its incidence worldwide. ATC accounts for more than half of the 1200 deaths per year attributed to thyroid cancer. Long-term survivors are rare, with > 75% and 50% of patients harboring cervical nodal disease and metastatic disease, respectively, at presentation. ATC can arise de novo or from preexisting well-differentiated thyroid cancer. Surgical management has shifted from tracheostomy only for palliation to curative resection when possible. Tracheostomy is performed for impending obstruction rather than for prophylaxis. Radiotherapy has evolved from postoperative administration only to preoperative treatment, combining preoperative and postoperative treatment and using higher doses, along with hyperfractionating and accelerating dose schedules. Chemotherapy has changed from monotherapy to combination therapy, and newer drugs such as paclitaxel show promise. Similarly, novel angiogenesis-inhibiting agents are currently being used, with early reports of some benefit. Conclusions: Despite multimodality approaches, ATC still carries a dismal prognosis. This should provoke innovative strategies beyond conventional methods to tackle this uniformly lethal disease.

AB - Background: Anaplastic thyroid carcinoma (ATC) is one of the most aggressive solid tumors known to affect humans and carries a dismal prognosis. Our primary aim was to review its epidemiology, biology, risk factors, and prognostic indicators. We also reviewed the individual and combined roles of surgery, radiotherapy, chemotherapy, and newer therapeutic options in the management of ATC. Methods: An extensive literature review was conducted to include all published reports on ATC. The changing trends in the management of anaplastic thyroid cancer were analyzed to summarize the current practice of management of ATC. Results: Although ATC is rare, there has been a decline in its incidence worldwide. ATC accounts for more than half of the 1200 deaths per year attributed to thyroid cancer. Long-term survivors are rare, with > 75% and 50% of patients harboring cervical nodal disease and metastatic disease, respectively, at presentation. ATC can arise de novo or from preexisting well-differentiated thyroid cancer. Surgical management has shifted from tracheostomy only for palliation to curative resection when possible. Tracheostomy is performed for impending obstruction rather than for prophylaxis. Radiotherapy has evolved from postoperative administration only to preoperative treatment, combining preoperative and postoperative treatment and using higher doses, along with hyperfractionating and accelerating dose schedules. Chemotherapy has changed from monotherapy to combination therapy, and newer drugs such as paclitaxel show promise. Similarly, novel angiogenesis-inhibiting agents are currently being used, with early reports of some benefit. Conclusions: Despite multimodality approaches, ATC still carries a dismal prognosis. This should provoke innovative strategies beyond conventional methods to tackle this uniformly lethal disease.

KW - Anaplastic thyroid carcinoma

KW - Biology

KW - Pathogenesis

KW - Prognostic factors

KW - Treatment approaches

UR - http://www.scopus.com/inward/record.url?scp=33644977631&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33644977631&partnerID=8YFLogxK

U2 - 10.1245/ASO.2006.05.042

DO - 10.1245/ASO.2006.05.042

M3 - Review article

C2 - 16474910

AN - SCOPUS:33644977631

VL - 13

SP - 453

EP - 464

JO - Annals of Surgical Oncology

JF - Annals of Surgical Oncology

SN - 1068-9265

IS - 4

ER -